Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of SARS-CoV-2 Disease on Immune Responses, Disease Severity and Treatment Outcomes in Pulmonary Tuberculosis

NCT04930978 is registered in ClinicalTrials.gov with Tuberculosis Research Centre, India as lead sponsor.

NCT NCT04930978
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04930978 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of SARS-CoV-2 Disease on Immune Responses, Disease Severity and Treatment Outcomes in Pulmonary Tuberculosis
Lead sponsor
Tuberculosis Research Centre, India
Phase
Observational
Overall status
Unknown status
Start date
June 21, 2021
Completion date
June 20, 2024
Enrollment
250 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 respiratory infection, pulmonary tuberculoses